Highlights
IIA supported (ever)1 patent
About
Lifecycle Management for Pharmaceuticals
Mapi Pharma is a clinical-stage pharmaceutical company developing proprietary pharmaceuticals, including lifecycle management products such as Depot long-acting injections, complex active pharmaceutical ingredients, and formulations.
The company’s lead product is Glatiramer Acetate Depot, a once-monthly injection for the treatment of patients with multiple sclerosis. Mapi is also engaged in the development of Pregabalin ER for the treatment of neuropathic pain and epilepsy, Paliperidone Palmitate and Buspirone ER for the treatment of schizophrenia, and other long-acting Depot injectable treatments.
Identity
| Name | Mapi Pharma |
|---|---|
| Slug | mapi-pharma |
| Type / kind | startup |
| Crunchbase ID | mapi-pharma |
| Source _id | agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgJ7frNsJDA |
Status
| Status | active |
|---|---|
| Last update | 2026-05-17 |
Location
| HQ country code | IL |
|---|---|
| HQ region/district | Center District |
| HQ city | Ness Ziona |
| HQ address | Einstein Street 16, Ness Ziona, Israel |
Web & social
| Website | https://mapi-pharma.com |
|---|---|
| https://www.linkedin.com/company/5229663 | |
| YouTube | https://www.youtube.com/channel/UCX1qdf5rKzaWtsUwJ_dxFVQ |
Classifications
Primary sector Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyDrugs Discovery & Development
Technologies
Biologicals
Target customers
Healthcare & Life SciencesLife SciencesPharmaceuticals
Business models
B2B
Tags
pain-reliefpharmaceuticalsdiabetesgeneric-drugsepilepsyschizophreniainflammatory-diseasespharma-companies
Funding
| Total raised | $42.5M |
|---|---|
| Current stage | Series A |
Raw source document
Show full JSON (0 KB)
{
"0": "s",
"1": "l",
"2": "i",
"3": "m",
"4": "p",
"5": "a",
"6": "g",
"7": "e",
"8": "s",
"9": "_",
"10": "i",
"11": "m",
"12": "p",
"13": "o",
"14": "r",
"15": "t"
}